UK Breast Cancer Diagnostics And Therapeutics Market Analysis, Size, Current Scenario and Future Prospects

UK breast cancer diagnostics and therapeutics market are estimated to grow significantly at a CAGR of 9.0% during the forecast period. Increasing the incidence of breast cancer coupled with governemnt intitives are the major factors that contributing to the growth of the market. According to Cancer Research UK, incidence rates for breast cancer are projected to rise by 2% in the UK between 2014 and 2035, to 210 cases per 100,000 females by 2035. The awareness programs and research funding on breast cancer also enable the growth of the market. In 2015 the Public Health England (PHE) launched the ‘Be Clear on Cancer’ campaign for the purpose of women aged 70 and over to drive awareness of the risk of breast cancer. Cancer Research UK funded about $38 million for breast cancer research in 2017. This funding enabled to create a network of research at 90 institutions in more than 40 states in the UK.

UK breast cancer diagnosis and therapeutics market are segmented on the basis of cancer type, diagnostics, and therapeutics. In cancer type segment market is further classified into ductal carcinoma in-situ (DCIS), invasive ductal carcinoma (IDC), triple negative breast cancer (TNBC), inflammatory breast cancer and others. In diagnostics technology, the segment market is further classified into mammography, biopsy, position emission tomography/computed tomography, ultrasound, and others. The therapeutics technology segment market is further segregated into chemotherapy, hormone therapy, targeted therapy, and others.

To Request a Sample of our Report on UK Breast Cancer Diagnostics And Therapeutics Market:   https://www.omrglobal.com/request-sample/uk-breast-cancer-diagnostics-therapeutics-market

UK Breast Cancer Diagnostics And Therapeutics Market Segmentation

 By Cancer type

  • Ductal Carcinoma In-Situ (DCIS)
  • Invasive Ductal Carcinoma (IDC)
  • Triple Negative Breast Cancer (TNBC)
  • Inflammatory Breast Cancer
  • Others (Invasive lobular carcinoma)

 By Diagnostics

  • Mammography
  • Biopsy
  • PET/CET
  • Ultrasound
  • Others (MRI)

By Therapeutics

  • Chemotherapy
  • Hormone Therapy
  • Targeted Therapy
  • Others (Radiation Therapy, Surgery)

A full Report of UK Breast Cancer Diagnostics And Therapeutics Market is Available @  https://www.omrglobal.com/industry-reports/uk-breast-cancer-diagnostics-therapeutics-market

Company Profiles

  • Agendia NV
  • AstraZeneca PLC
  • Bayer AG
  • GlaxoSmithKline PLC
  • Mylan NV
  • Merck & Co., Inc.
  • Novartis International AG
  • Hoffmann-La Roche AG
  • Sanofi S.A.
  • Siemens Healthcare GmbH

Reasons to buy from us –

  1. We cover more than 15 major industries, further segmented into more than 90 sectors.
  2. More than 120 countries are for analysis.
  3. Over 100+ paid data sources mined for investigation.
  4. Our expert research analysts answer all your questions before and after purchasing your report.

About Orion Market Research 

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offer Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.

Media Contact:

Company Name: Orion Market Research

Contact Person: Mr. Anurag Tiwari

Email: info@omrglobal.com

Contact no:  +91 7803040404